BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scribano ML. Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19? Dig Dis Sci. 2020;Online ahead of print. [PMID: 33073335 DOI: 10.1007/s10620-020-06624-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Otten AT, Bourgonje AR, Horinga PP, van der Meulen HH, Festen EAM, van Dullemen HM, Weersma RK, van Leer-buter CC, Dijkstra G, Visschedijk MC. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease. Front Immunol 2022;13:920333. [DOI: 10.3389/fimmu.2022.920333] [Reference Citation Analysis]
2 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022;39:2342-64. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nishida Y, Hosomi S, Fujimoto K, Nakata R, Sugita N, Itani S, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Nagami Y, Taira K, Kamata N, Watanabe T, Ohfuji S, Fujiwara Y. Impact of the Lockdown Due to the COVID-19 Pandemic on Patients With Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:649759. [PMID: 34957131 DOI: 10.3389/fmed.2021.649759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med 2021;10:5660. [PMID: 34884361 DOI: 10.3390/jcm10235660] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Bertani L, Barberio B, Tricò D, Zanzi F, Maniero D, Ceccarelli L, Marsilio I, Coppini F, Lorenzon G, Mumolo MG, Zingone F, Costa F, Savarino EV. Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. J Clin Med 2021;10:3270. [PMID: 34362053 DOI: 10.3390/jcm10153270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Oikonomou KG, Papamichalis P, Zafeiridis T, Xanthoudaki M, Papapostolou E, Valsamaki A, Bouliaris K, Papamichalis M, Karvouniaris M, Vlachostergios PJ, Skoura AL, Komnos A. Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions. World J Clin Cases 2021; 9(19): 4918-4938 [PMID: 34307544 DOI: 10.12998/wjcc.v9.i19.4918] [Reference Citation Analysis]
8 Möhn N, Konen FF, Pul R, Kleinschnitz C, Prüss H, Witte T, Stangel M, Skripuletz T. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. J Clin Med 2020;9:E4067. [PMID: 33339436 DOI: 10.3390/jcm9124067] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 12.5] [Reference Citation Analysis]